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Stress echocardiography is the combination of echocardiography
with a physical, pharmacological, or electrical stress. The diagnostic
endpoint for the detection of myocardial ischaemia is the induction
of a transient worsening in regional function during stress. Stress
echocardiography provides similar diagnostic and prognostic accu-
racy to radionuclide stress perfusion imaging, but at a substantially
lower cost, without environmental impact, and with no biohazards
for the patient and the physician.
Among different stresses of comparable diagnostic and prog-
nostic accuracy, semisupine exercise is the most used, dobuta-
mine the best test for viability, and dipyridamole the safest and
simplest pharmacological stress and the most suitable for com-
bined wall motion coronary flow reserve assessment. The
additional clinical benefit of myocardial perfusion contrast echo-
cardiography and myocardial velocity imaging has been inconsist-
ent to date, whereas the possibility of performing coronary flow
reserve evaluation of the left anterior descending coronary artery
by transthoracic Doppler echocardiography adds another poten-
tially important dimension to stress echocardiography. New
emerging fields of application taking advantage of the versatility
of the technique are Doppler stress echo in valvular heart
disease and in dilated cardiomyopathy. In spite of its dependence
on the operator’s training, stress echocardiography is today the
best (most cost-effective and risk-effective) possible imaging
choice to achieve the still elusive target of sustainable cardiac
imaging in the field of non-invasive diagnosis of coronary artery
disease.
Stress echo: a historical and
socio-economic perspective
In 1935, Tennant and Wiggers1 demonstrated that coronary occlu-
sion immediately resulted in instantaneous abnormality of wall
motion. A large body of evidence2 –5 recognized for the first
time that transient dys-synergy was an early, sensitive, specific
marker of transient ischaemia, clearly more accurate than ECG
changes and pain. In European clinical practice,6 – 10 stress echo
has been embedded in the legal and cultural framework of existing
European laws and medical imaging referral guidelines. The radi-
ation used for medical examinations and tests is the greatest
man-made source of radiation exposure.11 Small individual risks
of each test performed with ionizing radiation multiplied by a
billion examinations become significant population risks. For this
reason, in Europe, both the law11 and the referral guidelines for
medical imaging12 recommend a justified, optimized, and respon-
sible use of testing with ionizing radiation. European Commission
referral guidelines were released in 2001 in application of the
Euratom Directive, and explicitly state that a non-ionizing tech-
nique must be used whenever it will give information grossly com-
parable with an ionizing investigation. For instance, ‘because MRI
does not use ionizing radiation, MRI should be preferred when
both CT and MRI would provide similar information and when
both are available’.12 In this perspective of the medical, as well as
socio-economic and biological impact of medical imaging, it is
imperative to increase all efforts to improve appropriateness13
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and minimize the radiation burden of stress imaging for the popu-
lation and the individual patient.14 The imperative of sustainability
of medical imaging is likely to become increasingly important in
the near future, also from a US perspective.15,16 In the quest for
sustainability, stress echocardiography has unsurpassed assets
of low cost, absence of environmental impact, and lack of
biological effects for both the patient17 and the operator com-
pared with equally accurate, but less sustainable, competing
techniques.18
Pathophysiological mechanisms
Stress echocardiography is the combination of 2D echocardiogra-
phy with a physical, pharmacological, or electrical stress.19 The
diagnostic endpoint for the detection of myocardial ischaemia is
the induction of a transient change in regional function during
stress. The stress echo sign of ischaemia is a stress-induced wor-
sening of function in a region contracting normally at baseline.
The stress echo sign of myocardial viability is a stress-induced
improvement of function during low levels of stress in a region
that is abnormal at rest. A transient regional imbalance between
oxygen demand and supply usually results in myocardial ischaemia,
the signs and symptoms of which can be used as a diagnostic tool.
Myocardial ischaemia results in a typical ‘cascade’ of events in
which the various markers are hierarchically ranked in a well-
defined time sequence.20 Flow heterogeneity, especially between
the subendocardial and subepicardial perfusion, is the forerunner
of ischaemia, followed by metabolic changes, alteration in regional
mechanical function, and only at a later stage by electrocardio-
graphic changes, global left ventricular (LV) dysfunction, and pain.
The pathophysiological concept of the ischaemic cascade is trans-
lated clinically into a gradient of sensitivity of different available
clinical markers of ischaemia, with chest pain being the least and
regional malperfusion the most sensitive. This is the conceptual
basis of the undisputed advantages of imaging techniques, such as
perfusion imaging or stress echocardiography over electrocardio-
gram (ECG) for the non-invasive detection of coronary artery
disease.21 The reduction of coronary reserve is the common
pathophysiological mechanism. Regardless of the stress used and
the morphological substrate, ischaemia tends to propagate centri-
fugally with respect to the ventricular cavity:21,22 it involves primar-
ily the subendocardial layer, whereas the subepicardial layer is
affected only at a later stage if the ischaemia persists. In fact, extra-
vascular pressure is higher in the subendocardial than in the sube-
picardial layer; this provokes a higher metabolic demand (wall
tension being among the main determinants of myocardial
oxygen consumption) and an increased resistance to flow. In the
absence of coronary artery disease, coronary flow reserve (CFR)
can be reduced in microvascular disease (e.g. in syndrome X) or
LV hypertrophy (e.g. arterial hypertension). In this condition,
angina with ST-segment depression can occur with regional per-
fusion changes, typically in the absence of any regional wall
motion abnormalities during stress. Wall motion abnormalities
are more specific than CFR and/or perfusion changes for the diag-
nosis of coronary artery disease.23 –28
Key point: wall motion and perfusion (or CFR) changes
are highly accurate, and more accurate than ECG
changes, for detection and location of underlying coronary
artery disease. However, wall motion is more specific and
requires ischaemia; perfusion changes are more sensitive
and may occur in the absence of true ischaemia.
Ischaemic stressors
The three most common stressors are exercise, dobutamine, and
dipyridamole (Figures 1 and 2). Exercise is the prototype of
demand-driven ischaemic stress and the most widely used.
However, out of five patients, one cannot exercise, one exercises
submaximally, and one has an uninterpretable ECG. Thus, the use
of an exercise-independent approach allows the diagnostic domain
of a stress test laboratory to be expanded.29,30 Pharmacological
stressors minimize factors such as hyperventilation, tachycardia,
hypercontraction of normal walls, and excessive chest wall move-
ment, which render the ultrasonic examination difficult during
exercise. All these factors degrade image quality and—in stress
echo—worse image quality dramatically leads to higher interobser-
ver variability and lower diagnostic accuracy. Dipyridamole (or
adenosine) and dobutamine act on different receptor populations:
dobutamine stimulates adrenoreceptors whereas dipyridamole
(which accumulates endogenous adenosine) stimulates adenosine
receptors.31 They induce ischaemia through different haemo-
dynamic mechanisms: dobutamine primarily increases myocardial
oxygen demand32 and dipyridamole (or adenosine) mainly
decreases subendocardial flow supply33 (Table 1). In the presence
of coronary atherosclerosis, appropriate arteriolar dilation can
paradoxically exert detrimental effects on regional myocardial
layers or regions already well perfused in resting conditions at
the expense of regions or layers with a precarious flow balance
in resting conditions. In ‘vertical steal’, the anatomical requisite is
the presence of an epicardial coronary artery stenosis and the sub-
epicardium ‘steals’ blood from the subendocardial layers. The
mechanism underlying vertical steal is a fall in perfusion pressure
across the stenosis. In the presence of a coronary stenosis, the
administration of a coronary vasodilator causes a drop in post-
stenotic pressure and, therefore, a critical drop in subendocardial
perfusion pressure, which in turn provokes a decrease in absolute
subendocardial flow, even with subepicardial overperfusion.
Figure 1 State-of-the art protocol for dobutamine stress
echocardiography.
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Regional thickening is closely related to subendocardial rather than
transmural flow, and this explains the regional asynergy with
ischaemia, despite regionally increased transmural flow. Since
endocardial oxygen demands are greater than epicardial
demands, the resistance vessels of the endocardium are more
dilated than those of the subepicardium, ultimately resulting in
selective subendocardial hypoperfusion. ‘Horizontal steal’ requires
the presence of collateral circulation between two vascular beds,
with the victim of the steal being the myocardium fed by the
more stenotic vessel. The arteriolar vasodilatory reserve must be
preserved, at least partially, in the donor vessel and abolished in
the vessel receiving collateral flow. After vasodilation, the flow in
the collateral circulation is reduced in comparison with resting
conditions. Despite the different pathophysiological mechanism,
ischaemia induction when appropriately high doses with
state-of-the-art protocols are used, dipyridamole and dobutamine
tests show a similar diagnostic accuracy.34 –37
Key point: exercise, dobutamine, and vasodilators (at
appropriately high doses) are equally potent ischaemic
stressors for inducing wall abnormalities in the presence
of a critical epicardial coronary artery stenosis. Dobuta-
mine and exercise mainly act through increased myocar-
dial oxygen demand, and dipyridamole and adenosine
through reduced subendocardial flow supply subsequent
to inappropriate arteriolar vasodilation and steal
phenomena.
Diagnostic criteria
All stress echocardiographic diagnoses can be easily summarized
into equations centred on regional wall function describing the
fundamental response patterns as normal, ischaemic, viable, and
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 2 Stress echocardiography in four equations
Rest þ Stress ¼ Diagnosis
Normokinesis þ Normo- to hyperkinesis ¼ Normal








þ Akinesis to dyskinesis ¼ Necrosis
Figure 2 State-of-the art protocol for dipyridamole stress echocardiography.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 1 Pharmacological stresses
Vasodilator Dobutamine




Reduces supply Increases supply
Physiological targets Coronary arterioles Myocardium
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necrotic myocardium. In the normal response, a segment is nor-
mokinetic at rest and normal or hyperkinetic during stress. In
the ischaemic response, a segment worsens its function during
stress from normokinesis to hypokinesis, akinesis, or dyskinesis
(usually at least two adjacent segments are required for test posi-
tivity) (Table 2). In the necrotic response, a segment with resting
dysfunction remains fixed during stress. In the viability response,
a segment with resting dysfunction may show either a sustained
improvement during stress, indicating a non-jeopardized myocar-
dium (stunned), or improve during early stress with subsequent
deterioration at peak (biphasic response). This response would
indicate a jeopardized region (hibernating myocardium) often
improving after revascularization.19,38 A resting akinesis which
becomes dyskinesis during stress usually reflects a purely passive,
mechanical consequence of increased intraventricular pressure
developed by normally contracting walls, and should not be con-
sidered a true active ischaemia.39
As with most imaging techniques, patient-dependent factors can
limit image quality in stress echocardiography, which can adversely
affect accuracy. Obesity and lung disease, for example, may lead to
poor acoustic windows in 10% of patients. Harmonic imaging
and ultrasound contrast agents for LV opacification are now rec-
ommended to enhance endocardial border detection. Given that
the interpretation of contractile function is subjective, improved
image quality can reduce inter-reader variability.
Key point: all stress echo responses follow four basic
patterns: normal (rest5 stress5 normal function);
ischaemia (rest5 normal; stress 5 abnormal); necrotic
(rest5 stress 5 abnormal); and viability (rest5 abnor-
mal; stress 5 normal or biphasic). Clear endocardial defi-
nition is crucial for optimal interpretation and it is
recommended that harmonic imaging, when available,
be routinely used for optimal endocardial border detec-
tion. Contrast-enhanced endocardial border detection
could be used when suboptimal imaging is present.
Diagnostic accuracy
Exercise,23,40 –50 high-dose dobutamine,51 –55 and high-dose (accel-
erated or with atropine) dipyridamole29,35,36,46,52,56,57 have not
only similar accuracies, but also similar sensitivities.35,36,58 (Tables 3
and 4). Familiarity with all forms of stress is an index of the quality
of the echo lab. In this way, indications in the individual patient can
be optimized, thereby avoiding the relative and absolute contraindi-
cations of each test. For instance, a patient with severe hypertension
and/or a history of significant atrial or ventricular arrhythmias can
more reasonably undergo the dipyridamole stress test which,
unlike dobutamine, has no arrhythmogenic or hypertensive effect.
In contrast, a patient with severe conduction disturbances or
advanced asthmatic disease should undergo the dobutamine stress
test, since adenosine has a negative chronotropic and dromotropic
effect, as well as a documented bronchoconstrictor activity. Patients
either taking xanthine medication or under the effect of caffeine con-
tained in drinks (tea, coffee, and cola) should undergo the dobuta-
mine test. Both dipyridamole and dobutamine have overall
tolerance and feasibility. The choice of one test over the other
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physician’s preference. It is important for all stress echocardiography
laboratories to become familiar with all stresses in order to achieve a
flexible and versatile diagnostic approach that enables the best stress
to be tailored to individual patient needs. Antianginal medical
therapy (in particular,b-blocking agents) significantly affects the diag-
nostic accuracy of all forms of stress; therefore, it is recommended,
whenever possible, to withhold medical therapy at the time of testing
to avoid a false-negative result.
Key point: physical or pharmacological (inotropic or
vasodilator) stress echocardiography have comparable
diagnostic accuracies. The choice of one test over the
other will depend on relative contraindications. Large
volume laboratories should be fully acquainted with all
the three main forms of stress in order to apply the test
in all patients. In the presence of a submaximal first-line
stress for limiting side effects, the second choice should
be applied, since submaximal (physical or pharmacologi-
cal) stresses have suboptimal diagnostic value.
Prognostic value of inducible
myocardial ischaemia
The presence (or absence) of inducible wall motion abnormalities
separates patients with different prognoses. Information has been
obtained from data banks of thousands of patients—also with mul-
ticentre design—for exercise,59– 75 dobutamine,76 –80 and dipyrida-
mole.81– 85 A normal stress echocardiogram yields an annual risk of
0.4–0.9% based on a total of 9000 patients,75 the same as for a
normal stress myocardial perfusion scan. Thus in patients with sus-
pected coronary artery disease, a normal stress echocardiogram
implies excellent prognosis, and coronary angiography can safely
be avoided. The positive and the negative response can be
further stratified with interactions with clinical parameters (dia-
betes, renal dysfunction, and therapy at the time of test), resting
echo (global LV function), and additive stress echo parameters
(LV cavity dilatation, CFR, and previous revascularization). The
established prognostic stress echo parameters with their relative
event rates are shown in Tables 5 and 6.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .








Resting EF .50% ,40%
Anti-ischaemic therapy Off On
Coronary territory LCx/RCA LAD
Peak WMSI Low High
Recovery Fast Slow
Positivity or baseline dys-synergy Homozonal Heterozonal
CFR .2.0 ,2.0
CFR, coronary flow reserve; EF, ejection fraction; LAD, left anterior descending
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Key point: physical or pharmacological (inotropic or
vasodilator) stress echocardiography have a comparable
prognostic power of stratification. The most extensive evi-
dence is available with dipyridamole, dobutamine, and
exercise tests. A normal baseline and stress echocardio-
gram gives an annual risk for death of 0.4–0.9%, the
same as for a normal stress myocardial perfusion scan.
Thus, in patients with suspected coronary artery disease,
a normal stress echocardiogram implies an excellent
prognosis, and coronary angiography can safely be
avoided.
Indications and prognostic value of
myocardial viability assessment
By far the widest experience is available with low-dose dobutamine
stress echocardiography,6,7,86 –88 the preferred stressor for asses-
sing myocardial viability. However, it is also possible to assess
the presence of myocardial viability using low-dose dipyridamole,
low-level exercise, or enoximone.89 –94 In the setting of ischaemia,
loss of myocardial contractile function may be due to myocardial
necrosis, stunning, or hibernation. Whereas myocardial necrosis
usually alludes to irreversible myocardial dysfunction, stunning
and hibernation reflect reversibility of myocardial function. Revas-
cularization of chronically, but reversibly, dysfunctional myocar-
dium, often referred to as hibernating or viable, has emerged as
an important alternative in the treatment of heart failure secondary
to coronary artery disease. Observational studies have indeed
suggested that patients with ischaemic LV dysfunction and a signifi-
cant amount of viable myocardium [at least five segments or a wall
motion score index (WMSI) .0.25]95–104 have lower periopera-
tive mortality, greater improvements in regional and global LV
function, fewer heart failure symptoms, and improved long-term
survival after revascularization than patients with large areas of
non-viable myocardium.
Key point: dobutamine stress echocardiography is by far
the most widely used method for assessing viable myocar-
dium. This is highly recommended in patients with LV dys-
function who may benefit from coronary revascularization.
When dobutamine is contraindicated or not well tolerated,
several other stresses (low-level exercise, adenosine, dipyr-
idamole, and enoximone) can be used to elicit a regional
inotropic reserve in viable myocardium.
Safety of pharmacological stress
echocardiography
Minor, but limiting, side effects preclude the achievement of
maximal pharmacological stress in ,10% of patients with dobuta-
mine9 and ,5% in patients with dipyridamole stress.105 – 119 The
most frequent minor and major complications during stress echo
and their frequencies are shown in Tables 7–9. The data emphasize
some obvious, albeit sometimes neglected, points. First, pharmaco-
logical stress tests should always be performed with an attending
physician present. Secondly, every test carries a definite, albeit
minor risk. Thirdly, not all stress tests carry the same risk of
major adverse reactions, and dobutamine stress testing may be
more dangerous than other forms of pharmacological stress,
such as those produced by dipyridamole or adenosine. These con-
clusions come convergently from multicentre trials, meta-analyses
of published literature, and the Registry of Complications based on
prospective data acquisition (German Registry) and retrospective
data retrieval. Physical stress with exercise is probably safer than
pharmacological testing.118,119
Key point: exercise is safer than pharmacological stress.
Among pharmacological stresses, dipyridamole is safer
than dobutamine. Both the doctor and the patient
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Resting EF .50% ,40%
Anti-ischaemic therapy Off On
CFR .2.0 ,2.0
CFR, coronary flow reserve; EF, ejection fraction.
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Table 7 Life-threatening complications in single-centre
experience (>1000 patients), multicentre studies
(EDIC) and multicentre registries for dobutamine
stress echocardiography
Author, year Patients Complication(s)
Single institution
experience
Mertes et al., 1993 1118 Nonea
Pellikka et al., 1995 1000 1 AMI, 4 VT, 1 prol ischaemia
Zahn et al., 1996 1000 1 VF, 1 LVF, 1 seizure
Secknus and Marwick,
1997
3011 5 VT, 1 AMI, 1 prol ischaemia,
1 hypo
Elhendy et al., 1998 1164 7 VT
Bremer et al., 1998 1035 1 VF, 1 VT
Poldermans et al., 1994 1734 3 VF, 13 VT, 6 hypo
Mathias et al., 1999 4033 1 VF, 8 VT, 1 MI; 5 atropine
intoxications
Multicentre registry
Picano et al. (EDIC),
1994
2949 2 VF, 2 VT, 2 AMI, 1 prol
ischaemia, 1 hypo
Pezzano et al. (RITED),
1994
3041 2 VF, 1 asystole
Beckmann et al., 1999 9354 324 (2 VF)
Varga et al., 2006 35 103 63 (5 deaths)
Total 64 542 461
aNo life-threatening complications reported; however, minor and self-limiting
adverse effects were documented.
AMI, acute myocardial infarction; MI, myocardial infarction; prol, prolonged; hypo,
hypokinetic; VF, ventricular fibrillation; VT, ventricular tachycardia.
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should be aware of the rate of complications—and the rate
of complications (derived from literature and from the lab
experience) should be spelled out in the informed consent.
Indication for stress echo
Indications for stress echocardiography can also be grouped in very
broad categories:
(i) coronary artery disease diagnosis;
(ii) prognosis and risk stratification in patients with established
diagnosis (e.g. after myocardial infarction);
(iii) pre-operative risk assessment;
(iv) evaluation for cardiac aetiology of exertional dyspnoea;
(v) evaluation after revascularization;
(vi) ischaemia location;120
(vii) evaluation of heart valve stenosis severity.
As a rule, the less informative the exercise ECG test is, the stricter
the indication for stress echocardiography will be.
The five main specific indications for stress echocardiography
can be summarized as follows:
(i) patients in whom the exercise stress test is contraindicated
(e.g. patients with severe arterial hypertension);
(ii) patients in whom the exercise stress test is not feasible (e.g.
those with intermittent claudication);
(iii) patients in whom the exercise stress test was non-diagnostic
or yielded ambiguous results;
(iv) left bundle branch block or significant resting ECG changes
that makes any ECG interpretation during stress difficult;
(v) submaximal stress ECG.
Stress echocardiography yields the greatest incremental diagnostic
and prognostic value in patients in whom exercise electrocardio-
graphy is non-diagnostic, ambiguous, or inconclusive. Pharmaco-
logical stress echocardiography is the choice for patients in
whom exercise is not feasible or contraindicated. The results of
physical and pharmacological stress echo should be used in both
inpatients and outpatients as ‘a gatekeeper’ to coronary angiogra-
phy. In fact, for any given coronary anatomy, the prognostic
benefit of recanalization is much higher with documented ischae-
mia on stress testing. Patients with stress echo positivity, especially
those with a ‘high-risk’ positivity pattern (occurring at low dose or
workload, with slow recovery and/or antidote resistance, with
akinesis or dyskinesis of more than five segments of the left
ventricle), should be referred to coronary angiography. In
Table 10, several clinical targets of stress echocardiography are
reported.
Key point: stress echocardiography should not be used as
a first-line imaging technique for diagnostic and prognostic
purposes in patients with known or suspected coronary
artery disease, but only when the exercise ECG stress test
is either non-diagnostic or non-interpretable (e.g. for left
bundle branch block or pacemaker). The less informative
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Table 10 Clinical targets: coronary artery disease, dilated cardiomyopathy, valvular disease, and pulmonary
hypertension
Clinical condition Pathophysiological target Stress of choice Echo variable
Coronary artery disease Myocardial ischaemia Ex, Dob, Dip WM
Dilated cardiomyopathy Contractile reserve Dob (Ex, Dip) WM
Diabetes, hypertension, HCM Coronary flow reserve Dip (Dob, Ex) PW LAD
Transmitral gradient Increase in cardiac output Ex, Dob PW mitral
Transaortic gradient Increase in cardiac output Ex, Dob CW aortic
Pulmonary hypertension Pulmonarycongestion/vasoconstriction Ex CW TR
CW, continuous wave Doppler; DC, dilated cardiomyopathy; Dip, dipyridamole; Dob, dobutamine; Ex, exercise; HCM, hypertrophic cardiomyopathy; LAD, left anterior
descending coronary artery; PW, pulsed wave Doppler; TR, tricuspid regurgitation; WM, wall motion;
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 8 Life-threatening complications in multicentre
studies (EPIC) and multicentre registries for
dipyridamole stress echocardiography





10 451 1 cardiac death, 1 asystole, 2 AMI, 1
pulmonary oedema, 1 sustained VT
Varga et al.,
2006
24 599 19 (1 death)
Total 35 050 25
AMI, acute myocardial infarction; VT, ventricular tachycardia.
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Table 9 Safety profile of pharmacological stress
echocardiography
Dobutamine Dipyridamole
% submaximal tests 10% 5%
Side effects 1/300 exams 1/1000
VT, VF þþ þ
High grade AV block þ þþ
Death 1/5000 1/10000
AV, arteriovenous; VF, ventricular fibrillation; VT, ventricular tachycardia.
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and/or interpretable exercise electrocardiography is,
the higher is the level of appropriateness to stress echocar-
diography. No new technology application to stress echo-
cardiography is routinely recommended.
New technologies applied to stress
echocardiography
The state-of-the art diagnosis of ischaemia in stress echocardiography
remains the eyeballing interpretation of regional wall motion in black
and white cine loops. New quantitative techniques can objectify
regional myocardial function assessment and, thus, have the potential
to reduce observer dependence and to shorten learning curves.121
Doppler- and speckle tracking-based myocardial velocity and defor-
mation measurements have been proposed, and shown to detect
ischaemia and to predict patient outcome.121,122 Data noise and time-
consuming analysis are issues that still need to be solved in Doppler-
based approaches. Speckle tracking- and 3D echocardiography-
derived data have currently insufficient temporal resolution for the
high heart rates of a bicycle or dobutamine stress test.
Comparison with competing
techniques: cost and risk
assessment
Given the many factors affecting the value of diagnostic accuracy,
reliable information on the relative value of different tests can
only be gained by studying an adequate number of patients in
head-to-head comparison under the same conditions. When com-
pared with standard exercise electrocardiography testing, stress
echocardiography has an advantage in terms of sensitivity and a
particularly impressive advantage in terms of specificity. In recent
guidelines, the advantages of stress echocardiography over per-
fusion scintigraphy include higher specificity, greater versatility,
greater convenience, and lower cost.123 The advantages of stress
perfusion imaging include a higher technical success rate, higher
sensitivity (especially for single-vessel disease involving the left cir-
cumflex), better accuracy when multiple resting LV wall motion
abnormalities are present, and a more extensive database for the
evaluation of prognosis.124,125 The ESC Guidelines on stable
angina conclude that ‘On the whole, stress echo and stress per-
fusion scintigraphy, whether using exercise or pharmacological
stress (inotropic or vasodilator), have very similar applications.
The choice as to which is employed depends largely on local facili-
ties and expertise’.120 Cardiac magnetic resonance (CMR) is the
latest technique to enter the field of cardiac imaging.126 –130 The
advantages of the technique are related to the absence of ionizing
radiation, at the price of higher costs and lower availability when
compared with echocardiography. Despite the high costs, the
time of image acquistion, safety profile, and low availability make
CMR an excellent option only when stress echocardiography is
inconclusive or not feasible.13 The high cost of stress imaging pro-
cedures warrants some financial justification, and three arguments
have been proposed.
First, a negative stress imaging test implies such a low risk of an
event that revascularization could not be justified on prognostic
grounds. Secondly, compared with simple stress testing, the use
of imaging tests in particular situations has been shown to
reduce downstream costs (both diagnostic and therapeutic).
Thirdly, several studies have shown that in comparison with coron-
ary angiography (where the detection of coronary stenoses seems
to lead inexorably to coronary intervention), decision-making
based on functional testing is associated with similar outcomes at
lower levels of downstream cost. On the basis of this large body
of evidence assessing the comparable accuracy of stress echo
and perfusion scintigraphy, the choice of one test over the other
will depend on the overall biological risk related to the use of radi-
ations. This is recommended by the executive European Law
(1997) and the European Commission Medical Imaging Guidelines
(2001). EU Medical Imaging Guidelines and the European law
(Euratom directive 97/43) state that a radiological (and medico-
nuclear) examination can be performed only ‘when it cannot be
replaced by other techniques that do not employ ionising radiation’
and it should always be justified (article 3: ‘if an exposure cannot be
justified it should be prohibited’). At patient level, the effective
dose of a single nuclear cardiology stress imaging scan ranges
from 10 to 27 mSv (with dual isotope imaging protocol). The cor-
responding equivalent dose exposure is 500 chest X-rays (sesta-
mibi), 1200 chest X-rays (thallium), and 1300 chest X-rays (dual
isotope protocol). According to the latest and most authoritative
estimates of BEIR VII, the estimated risk of cancer for a
middle-aged patient ranges from 1 in 1000 (for a sestamibi) to 1
in 400 (for a dual isotope scan). Therefore, in an integrated
risk–benefit balance, stress echo has shown advantages when
compared with imaging techniques such as scintigraphy.13,17,131
Key point: stress echocardiography should be preferred
due to its lower cost, wider availability, and—most impor-
tantly— for its radiation-free nature. Stress scintigraphy
offers similar information to stress echocardiography,
but with a radiation burden equivalent to between 600
and 1300 chest X-rays for every single stress scintigraphy.
This poses a significant biological risk both for the individ-
ual and for society, since small individual risks multiplied
by millions of stress tests per year become a significant
population burden.
For the complete document refer to: Sicari R, Nihoyannopoulos
P, Evangelista A, Kasprzak J, Lancellotti P, Poldermans D, Voigt JU,
Zamorano JL; European Association of Echocardiography. Stress
echocardiography expert consensus statement: European Associ-
ation of Echocardiography (EAE) (a registered branch of the
ESC). Eur J Echocardiogr 2008;9:415–437.
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